Phenytoin

證據等級: L5

預測適應症: 10 個

Phenytoin: From Epilepsy to Trigeminal Neuralgia

One-Sentence Summary

Phenytoin (Dilantin®) is a first-generation antiepileptic drug that suppresses abnormal neuronal firing through voltage-gated sodium channel blockade, historically used for tonic-clonic seizures and partial-onset epilepsy. Among 10 predicted new indications generated by the TxGNN model, trigeminal neuralgia emerges as the most clinically actionable target — the top-ranked prediction (trigeminal nerve neoplasm) is flagged as a likely knowledge graph artifact and is not recommended for advancement. The trigeminal neuralgia prediction is supported by 1 prospective clinical study (NCT03712254, completed) and 19 publications, including a 2019 European Academy of Neurology guideline that already positions IV phenytoin as an acute rescue option.

Quick Overview

Item	Content
Original Indication	Epilepsy / Seizure Disorders (established pharmacological use; no Philippines registration on file)
Predicted New Indication	Trigeminal Neuralgia (most actionable among 10 predictions; TxGNN Model Rank #461)
TxGNN Prediction Score	99.97%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Multi-Indication Prediction Overview

This candidate covers 10 predicted indications (ID: TW-DB00252-multi). The table below shows all predictions; trigeminal neuralgia is selected as the primary focus due to its superior evidence level and actionable recommendation.

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Trigeminal nerve neoplasm	99.99%	L5	Hold ⚠️ Likely KG artifact
2	Orgasm-induced seizures	99.98%	L5	Hold
3	Audiogenic seizures	99.98%	L3	Research Question
4	Startle epilepsy	99.98%	L4	Hold
5	Micturation-induced seizures	99.98%	L4	Research Question
6	Thinking seizures	99.98%	L4	Hold
7	Eating seizures	99.98%	L4	Hold
8	Reading seizures	99.97%	L4	Hold
9	Trigeminal neuralgia	99.97%	L2	✅ Proceed with Guardrails
10	Beta-ketothiolase deficiency	99.95%	L5	Hold ⚠️ Likely false positive

Rank #1 note: Trigeminal nerve neoplasm shares anatomical nodes with trigeminal neuralgia in the knowledge graph, artificially inflating the score. Phenytoin has no known antitumour mechanism and is not cytotoxic. This prediction should not proceed.

Rank #10 note: Beta-ketothiolase deficiency is a mitochondrial organic acidemia with no overlap with sodium channel biology. The high score reflects broad neurological node connectivity in the graph — a known false-positive pattern.

Why is This Prediction Reasonable?

Phenytoin’s core mechanism is use-dependent blockade of voltage-gated sodium channels (Nav). By preferentially binding inactivated Nav channels during high-frequency neuronal firing, it selectively suppresses repetitive discharges without affecting normal low-frequency activity. The Nav1.6 subtype — the dominant isoform expressed in large-diameter trigeminal sensory neurons and the trigeminal ganglion — is the precise molecular target through which phenytoin exerts its antiepileptic effect.

Trigeminal neuralgia (TN) is characterised by paroxysmal, lancinating facial pain driven by ectopic discharge at the trigeminal nerve root entry zone, typically resulting from focal demyelination caused by vascular compression. The resulting aberrant, high-frequency burst firing is mechanistically equivalent to the epileptic discharges phenytoin was designed to suppress — making the pharmacological bridge between epilepsy and TN exceptionally direct. This explains why phenytoin was the first drug ever shown to relieve trigeminal neuralgia (Bergouignan, 1942), nearly two decades before carbamazepine.

Today, oral carbamazepine and oxcarbazepine have displaced phenytoin as first-line maintenance therapy due to superior randomised evidence. However, intravenous (IV) phenytoin and its prodrug fosphenytoin retain a well-defined clinical niche: acute rescue during TN crises, when patients cannot swallow oral medication because chewing, talking, or eating triggers attacks. Multiple retrospective cohorts, the 2019 EAN guideline, and a completed prospective study (NCT03712254) all document this specific use case, confirming that the TxGNN prediction reflects genuine mechanistic and clinical alignment — not a computational artefact.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03712254	N/A	Completed	15	Prospective systematic study specifically evaluating IV phenytoin for acute trigeminal neuralgia exacerbations; designed to address the unmet need for parenteral treatment when oral intake triggers pain attacks

Only 1 registered trial directly evaluates phenytoin in trigeminal neuralgia. Complementary clinical evidence comes from the retrospective cohort studies listed in the Literature table below.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30860637	2019	Clinical Guideline	European Journal of Neurology	EAN comprehensive guideline on TN management; recognises IV phenytoin as a rescue option for acute pain crises
35469475	2022	Prospective Case Series	Cephalalgia	Descriptive study of 144 TN patients treated with IV lacosamide vs. IV phenytoin for acute exacerbations; directly evaluates effectiveness and safety of both agents
32981076	2020	Case Series	Headache	Retrospective cohort assessing IV phenytoin as acute rescue treatment for TN crises; reports response rates, time-to-relief, and tolerability
31908187	2020	Narrative Review	Molecular Pain	Comprehensive overview of TN pathophysiology and pharmacological treatments; explains the mechanistic basis for Nav channel blockers at the level of the trigeminal ganglion
28761370	2017	Analytical Review	Journal of Pain Research	Critical appraisal of phenytoin vs. carbamazepine in TN; argues phenytoin has been underutilised and that the evidence base is stronger than marketing history implies
39993829	2024	Review Article	Clinical Medicine & Research	In-hospital management of acute TN pain crises; IV phenytoin positioned as an established parenteral option alongside lacosamide
38421578	2024	Systematic Review	CNS Drugs	Systematic review of neuropathic pain management in multiple sclerosis including MS-related TN; covers Na⁺ channel blocker pharmacology and clinical evidence
29114270	2017	Review	Asian Journal of Neurosurgery	Comprehensive TN review covering etiology, pathogenesis, and management; documents phenytoin’s historical role as the first effective medical treatment
19445753	2009	Review	BMJ Clinical Evidence	Evidence-based review of TN treatments; anticonvulsants including phenytoin discussed as primary medical management options
15062534	2004	Review	Neurologic Clinics	Reviews antiepileptic drugs as the most effective agents for TN and glossopharyngeal neuralgia; phenytoin included as a clinically active option

Philippines Market Information

Phenytoin is currently not registered in the Philippines. No product authorizations were found in the regulatory database (0 licenses on file).

Despite the absence of a local registration, phenytoin and fosphenytoin are listed on the WHO Model List of Essential Medicines and are commercially available in many countries. Potential regulatory pathways in the Philippines include compassionate use programmes, importation under the Food and Drug Administration’s Special Access Scheme, or a formal New Drug Application targeting the IV/acute-use indication.

Safety Considerations

Formal safety data (package insert warnings and contraindications) were not retrievable in this Evidence Pack. Please refer to the phenytoin package insert for complete safety information.

Based on well-established clinical pharmacology, the following concerns are particularly relevant for the proposed trigeminal neuralgia use case:

Narrow therapeutic index: Phenytoin exhibits non-linear (zero-order) pharmacokinetics at therapeutic doses; small dose increases can cause disproportionate rises in plasma concentration, leading to toxicity (nystagmus, ataxia, encephalopathy). Therapeutic drug monitoring (TDM) is mandatory.
Cardiovascular hazard with IV administration: Rapid IV infusion causes bradycardia, hypotension, and ventricular arrhythmia; maximum infusion rate must not exceed 50 mg/min. Cardiac monitoring is required.
Drug interactions: Phenytoin is a potent CYP2C9/CYP3A4 inducer and is also CYP2C9-metabolised; clinically significant interactions occur with warfarin, oral contraceptives, antifungals, and many antiepileptics.
Gingival hyperplasia: Affects 50–60% of patients on chronic oral therapy; less relevant for acute IV use.
Teratogenicity: Associated with fetal hydantoin syndrome; avoid in pregnancy unless no alternative exists.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Phenytoin has a mechanistically validated and historically documented role in trigeminal neuralgia through Nav1.6 channel blockade of ectopic trigeminal discharges; a completed prospective study (NCT03712254), a large retrospective cohort (n=144, PMID 35469475), and the 2019 EAN guideline all support IV phenytoin as an acute rescue option — providing sufficient L2-level evidence to justify cautious clinical advancement, particularly for the parenteral acute-use indication where no well-established oral alternative is accessible.

To proceed, the following is needed:

Publish or obtain NCT03712254 results: The completed prospective study is the single most important data source; response rate, NRS pain score change, and adverse event data are needed before formal recommendation
Philippines regulatory pathway: Identify whether a Special Access Scheme or compassionate use designation can allow access to IV phenytoin/fosphenytoin given the current non-marketed status
Full safety dossier (Blocking — DG001): Download and parse the complete phenytoin package insert to resolve contraindication and drug-interaction gaps before any clinical safety review (S1 stage)
MOA documentation (High — DG002): Complete the DrugBank pharmacology query to formally document Nav subtype specificity and confirm mechanistic rationale
IV vs. oral distinction: Define the repurposing programme scope — acute IV rescue (stronger evidence, clear unmet need) vs. chronic oral maintenance (carbamazepine already preferred)
TDM protocol: Develop a therapeutic drug monitoring plan (target free phenytoin 1–2 mg/L; total 10–20 mg/L) given phenytoin’s narrow therapeutic index in a TN patient population

⚠️ This report is intended for research purposes only and does not constitute medical advice. All drug repurposing candidates require rigorous clinical validation before therapeutic application. Predictions generated by TxGNN are computational outputs and must be interpreted alongside clinical expertise.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.